Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LEVOPHED vs ANGIOTENSIN ll ACETATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Norepinephrine acts predominantly on alpha-1 adrenergic receptors to cause vasoconstriction and increase blood pressure. It also has beta-1 adrenergic receptor agonist activity, resulting in positive inotropic effects on the heart.
Angiotensin II acetate is a synthetic peptide that acts as a potent vasoconstrictor by binding to the angiotensin II type 1 (AT1) receptor on vascular smooth muscle cells, leading to increased intracellular calcium and smooth muscle contraction. It also stimulates aldosterone secretion from the adrenal cortex, promoting sodium and water retention.
Treatment of hypotension in acute hypotensive states (e.g., septic shock, myocardial infarction, blood loss),Adjunct in the treatment of cardiac arrest (off-label)
Treatment of hypotension in adults with septic or other distributive shock (FDA approved)
Initial dose: 8-12 mcg/min intravenously, titrate to desired blood pressure; typical maintenance: 2-4 mcg/min IV continuous infusion.
Intravenous infusion: 1-40 ng/kg/min titrated to achieve target blood pressure. Initial rate: 10 ng/kg/min.
The terminal elimination half-life is approximately 2 minutes. The clinical effect is short-lived due to rapid reuptake and metabolism; continuous intravenous infusion is required for sustained effect.
Terminal elimination half-life is approximately 30-60 minutes; clinical effect is short-lived requiring continuous intravenous infusion.
Primarily metabolized in the liver by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO).
Primarily metabolized by aminopeptidases and other peptidases in plasma and tissues, with minimal hepatic involvement.
Norepinephrine is primarily metabolized in the liver and other tissues by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). Less than 5% is excreted unchanged in urine. Metabolites are excreted renally (approximately 80-95% as normetanephrine, vanillylmandelic acid, and other conjugates).
Primarily renal (90-100%) as unchanged drug; minimal biliary/fecal elimination (<10%).
Approximately 25-30% bound to albumin and other plasma proteins.
Approximately 30% bound to plasma proteins, primarily albumin.
Approximately 0.7-1.0 L/kg. This indicates moderate distribution into tissues and plasma, consistent with a hydrophilic catecholamine.
Approximately 0.3-0.5 L/kg; indicates distribution mainly in extracellular fluid.
Bioavailability is 100% via intravenous administration. Oral bioavailability is negligible due to extensive first-pass metabolism; not administered orally. Intramuscular or subcutaneous administration results in erratic absorption and significant vasoconstriction leading to poor bioavailability; thus, intravenous infusion is the only reliable route.
Intravenous: 100%; subcutaneous/intramuscular: not well absorbed due to rapid local metabolism; oral: negligible (<1%) due to extensive first-pass metabolism.
No specific dose adjustment required for renal impairment; titrate to clinical response.
No specific dose adjustment required for renal impairment. Use caution in patients with renal artery stenosis.
No specific dose adjustment required for hepatic impairment; titrate to clinical response.
No specific dose adjustment required for hepatic impairment.
Initial: 0.05-0.1 mcg/kg/min IV continuous infusion, titrate to effect; maximum dose not established.
Intravenous infusion: 0.5-20 ng/kg/min titrated to effect. Safety and efficacy not established in neonates.
Start at lower end of dosing range (2-4 mcg/min IV) due to increased sensitivity and comorbidities; titrate cautiously.
Start at lower end of dosing range (1-5 ng/kg/min) due to potential for decreased renal function and increased sensitivity.
No FDA boxed warning exists for LEVOPHED.
No boxed warnings.
Risk of extravasation leading to tissue necrosis; ensure proper IV access and avoid infiltration,Monitor blood pressure, heart rate, and cardiac output continuously,May cause ischemia to limbs, kidneys, and splanchnic organs due to vasoconstriction,Use with caution in patients with hypertension, hyperthyroidism, or myocardial ischemia,Abrupt discontinuation may cause rebound hypotension
Thrombotic and thromboembolic events: Increased risk of venous and arterial thromboembolic events, including deep vein thrombosis, pulmonary embolism, and myocardial infarction.,Ischemic events: May cause cardiac ischemia and reduce cardiac output; use with caution in patients with coronary artery disease.,Vascular thrombosis: High risk of vascular thrombosis in patients with a history of thrombosis or hypercoagulable states.,Use in hypovolemia: Correct hypovolemia before administration to avoid exacerbation of vasoconstriction.,Pregnancy: May cause fetal harm; avoid use in pregnant women unless potential benefit outweighs risk.
Hypersensitivity to norepinephrine or any component of the formulation,Hypovolemia (should be corrected before or during therapy),Use with cyclopropane or halothane anesthesia (increases risk of ventricular arrhythmias),Severe peripheral vascular disease with risk of gangrene
Hypersensitivity to angiotensin II acetate or any component of the formulation,No absolute contraindications listed by the manufacturer; however, use is avoided in patients with uncorrected hypovolemia and those with a history of thromboembolic events.
No clinically significant food interactions. Monitor for hyperglycemia in diabetic patients due to alpha-adrenergic effects.
No food interactions specific to angiotensin II acetate. Maintain a balanced diet as tolerated. Avoid excessive salt intake unless directed otherwise, as it may counteract the medication's effect on blood pressure.
Norepinephrine is a catecholamine that does not cross the placenta extensively. Animal studies have not shown teratogenicity, but human data are limited. Inadequate uteroplacental blood flow due to maternal vasoconstriction may cause fetal hypoxia and bradycardia. Use only if clearly needed, and monitor fetal heart rate. FDA Pregnancy Category C.
First trimester: Potential for teratogenicity (increased risk of cardiovascular and CNS malformations). Second and third trimesters: Fetal hypotension, anuria, oligohydramnios, skull hypoplasia, pulmonary hypoplasia, and death. Use contraindicated in pregnancy.
Norepinephrine is not expected to be excreted into breast milk in clinically significant amounts due to its short half-life and rapid metabolism. M/P ratio not established. Use with caution in breastfeeding women, as effects on the infant are unknown.
No data on M/P ratio. Likely excreted in breast milk. Avoid breastfeeding due to unknown risks to neonate.
Pregnancy may alter the pharmacokinetics of norepinephrine, but specific dose adjustments are not established. Monitor maternal blood pressure closely and titrate to the lowest effective dose to maintain adequate uteroplacental perfusion. Starting dose is typically 0.5-1 mcg/min, titrated to effect.
No dose adjustment recommended if used; however, if inadvertently exposed, discontinue drug. Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced clearance) may lower drug levels, but no established dose adjustment.
LEVOPHED (norepinephrine) is a first-line vasopressor for septic shock. Administer via central line to avoid extravasation injury; if extravasation occurs, treat with phentolamine 5-10 mg in 10 m L saline infiltrated locally. Titrate to mean arterial pressure (MAP) ≥ 65 mm Hg. Taper gradually to avoid rebound hypotension.
ANGIOTENSIN II ACETATE is a vasoconstrictor used for refractory hypotension in distributive shock. Administer via central line to avoid extravasation, which can cause severe tissue ischemia. Monitor blood pressure every 5 minutes during titration. Discontinue other vasopressors if possible to avoid additive arrhythmogenic effects. Use with caution in patients with coronary artery disease or previous myocardial infarction due to increased oxygen demand. Taper gradually to avoid rebound hypotension.
This medication is used to treat dangerously low blood pressure.,It will be given intravenously (IV) in a hospital setting by healthcare professionals.,You may feel anxiety, headache, or heart palpitations as the medication works.,Report any pain, redness, or swelling at the IV site immediately.,Do not stop the medication abruptly; it must be tapered under medical supervision.
This medication is given intravenously in the hospital to raise very low blood pressure. You will be closely monitored during treatment.,Inform your healthcare provider immediately if you experience chest pain, difficulty breathing, or irregular heartbeat.,Avoid sudden position changes to prevent dizziness, as blood pressure may fluctuate.,Report any pain, swelling, or color changes at the injection site, which could indicate medication leakage.,You may need regular blood tests to monitor kidney function and electrolyte levels.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LEVOPHED vs ANGIOTENSIN ll ACETATE, answered by our medical review team.
LEVOPHED is a Vasopressor that works by Norepinephrine acts predominantly on alpha-1 adrenergic receptors to cause vasoconstriction and increase blood pressure. It also has beta-1 adrenergic receptor agonist activity, resulting in positive inotropic effects on the heart.. ANGIOTENSIN ll ACETATE is a Vasopressor that works by Angiotensin II acetate is a synthetic peptide that acts as a potent vasoconstrictor by binding to the angiotensin II type 1 (AT1) receptor on vascular smooth muscle cells, leading to increased intracellular calcium and smooth muscle contraction. It also stimulates aldosterone secretion from the adrenal cortex, promoting sodium and water retention.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LEVOPHED and ANGIOTENSIN ll ACETATE depend on the specific clinical indication. These are both Vasopressor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LEVOPHED is: Initial dose: 8-12 mcg/min intravenously, titrate to desired blood pressure; typical maintenance: 2-4 mcg/min IV continuous infusion.. The standard adult dose of ANGIOTENSIN ll ACETATE is: Intravenous infusion: 1-40 ng/kg/min titrated to achieve target blood pressure. Initial rate: 10 ng/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LEVOPHED and ANGIOTENSIN ll ACETATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LEVOPHED is classified as Category C. Norepinephrine is a catecholamine that does not cross the placenta extensively. Animal studies have not shown teratogenicity, but human data are limited. Inadequate uteroplacental . ANGIOTENSIN ll ACETATE is classified as Category C. First trimester: Potential for teratogenicity (increased risk of cardiovascular and CNS malformations). Second and third trimesters: Fetal hypotension, anuria, oligohydramnios, sku. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.